Adial Pharmaceuticals, Inc. (ADIL)
3.92
-0.30
(-7.11%)
USD |
NASDAQ |
Oct 23, 16:00
4.05
+0.13
(+3.32%)
After-Hours: 20:00
Adial Pharmaceuticals Net Income (Quarterly) : -51.99M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -51.99M |
| March 31, 2026 | -2.022M |
| December 31, 2025 | -1.996M |
| September 30, 2025 | -1.794M |
| June 30, 2025 | -1.959M |
| March 31, 2025 | -2.229M |
| December 31, 2024 | -2.071M |
| September 30, 2024 | -2.192M |
| June 30, 2024 | -2.458M |
| March 31, 2024 | -6.477M |
| December 31, 2023 | -1.904M |
| September 30, 2023 | -1.348M |
| June 30, 2023 | -1.510M |
| March 31, 2023 | -2.240M |
| December 31, 2022 | -2.550M |
| September 30, 2022 | -2.551M |
| June 30, 2022 | -3.237M |
| March 31, 2022 | -2.908M |
| December 31, 2021 | -5.831M |
| September 30, 2021 | -4.318M |
| June 30, 2021 | -4.441M |
| Date | Value |
|---|---|
| March 31, 2021 | -4.834M |
| December 31, 2020 | -3.469M |
| September 30, 2020 | -3.336M |
| June 30, 2020 | -1.811M |
| March 31, 2020 | -2.277M |
| December 31, 2019 | -2.058M |
| September 30, 2019 | -1.716M |
| June 30, 2019 | -2.134M |
| March 31, 2019 | -2.683M |
| December 31, 2018 | -1.269M |
| September 30, 2018 | -8.191M |
| June 30, 2018 | -1.792M |
| March 31, 2018 | -0.379M |
| December 31, 2017 | -0.404M |
| September 30, 2017 | -0.2926M |
| June 30, 2017 | -0.2643M |
| March 31, 2017 | -0.1786M |
| December 31, 2016 | -0.0955M |
| September 30, 2016 | -0.1034M |
| June 30, 2016 | -0.0957M |
| March 31, 2016 | -0.1256M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 51.99M |
| EPS Diluted (Quarterly) | -11.25 |
| Enterprise Value | 43.93M |
| Earnings Yield | -422.0% |
| Normalized Earnings Yield | -252.20 |